TY  - GEN
AU  - Zhou,Kexun
AU  - Jiang,Chenlu
AU  - Li,Qiu
TI  - Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
SN  - 1872-8332
PY  - 2020///0721
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - B7-H1 Antigen
KW  - antagonists & inhibitors
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Health Care Costs
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Markov Chains
KW  - Molecular Targeted Therapy
KW  - Prognosis
KW  - Propensity Score
KW  - Quality of Life
KW  - Randomized Controlled Trials as Topic
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.lungcan.2019.08.028
ER  -